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Abstract 
Background: Prenatal sex steroids have been associated with autism in several clinical and epidemiological studies. 
It is unclear how this relates to the autistic traits of the mother and how early this can be detected during pregnancy 
and postnatal development.
Methods: Maternal serum was collected from pregnant women (n = 122) before or during their first ultrasound 
appointment [mean = 12.7 (SD = 0.7) weeks]. Concentrations of the following were measured via immunoassays: tes‑
tosterone, estradiol, dehydroepiandrosterone sulphate, progesterone; and sex hormone‑binding globulin which was 
used to compute the free fractions of estradiol (FEI) and testosterone (FTI). Standardised human choriogonadotropin 
(hCG) and pregnancy‑associated plasma protein A (PAPP‑A) values were obtained from clinical records corresponding 
to the same serum samples. Mothers completed the Autism Spectrum Quotient (AQ) and for their infants, the Quanti‑
tative Checklist for Autism in Toddlers (Q‑CHAT) when the infants were between 18 and 20 months old.
Results: FEI was positively associated with maternal autistic traits in univariate (n = 108, Pearson’s r = 0.22, p = 0.019) 
and multiple regression models (semipartial r = 0.19, p = 0.048) controlling for maternal age and a diagnosis of PCOS. 
Maternal estradiol levels significantly interacted with fetal sex in predicting infant Q‑CHAT scores, with a positive 
relationship in males but not females (n = 100, interaction term: semipartial r = 0.23, p = 0.036) after controlling for 
maternal AQ and other covariates. The opposite was found for standardised hCG values and Q‑CHAT scores, with a 
positive association in females but not in males (n = 151, interaction term: r = −0.25, p = 0.005).
Limitations: Sample size of this cohort was small, with potential ascertainment bias given elective recruitment. Clini‑
cal covariates were controlled in multiple regression models, but additional research is needed to confirm the statisti‑
cally significant findings in larger cohorts.
Conclusion: Maternal steroid factors during pregnancy are associated with autistic traits in mothers and their infants.
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Background
Autism is a neurodevelopmental condition characterised 
by difficulties in social communication alongside unusu-
ally restricted interests, repetitive behaviour and frequent 
sensory hypersensitivity [4]. Co-occurring clinical con-
ditions are common and include learning difficulties, 
sleep disorders and nutritional intolerances [19]. Diag-
nosis of autism is possible as early as 18  months of age 
[27]. Autistic traits exist along a spectrum in the wider 
population [11]. This can be measured in infancy, as 
demonstrated by the Quantitative Checklist for Autism 
in Toddlers (Q-CHAT), a novel, dimensional measure of 
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autistic traits shown to predict later autism diagnosis in 
several validation studies [2, 3, 43].
Autism is diagnosed more often in males than in 
females, despite increasing awareness of its differential 
presentation in females [33]. The reasons for this gender 
ratio likely reflect both prenatal biology (genetics and sex 
steroids) and limitations in current diagnostic methods 
[32]. In the general population, there are on average, sex 
differences in specific psychological traits (e.g. systemis-
ing and empathising), which are shifted towards a “male” 
profile in autistic individuals of both genders [8, 23].
Several lines of evidence indicate that prenatal sex ster-
oid hormones may be mediating autism likelihood. First, 
a study of neuroanatomical differences between autistic 
and neurotypical brains revealed autistic females have 
atypical structure in regions that substantially overlap 
with sexually dimorphic regions in neurotypical controls. 
This suggests that autism affects female brains in regions 
related to sexual differentiation, which is in turn regu-
lated by prenatal sex steroid hormones [31]. This male-
shift is also evident in childhood, as indicated by studies 
showing that facial features of autistic boys, girls and 
their siblings are masculinised compared to neurotypical 
controls [48, 49]. Autistic males also have higher levels 
of steroid hormones in amniotic fluid, when these were 
assessed in a multivariate analysis, as well as higher lev-
els of estrogens in particular in univariate analyses of the 
same amniotic fluid samples [9, 10]. Additionally, estra-
diol levels are elevated in maternal serum of pregnancies 
linked to a later autism diagnosis in the child [13].
Traits and developmental profiles related to autism 
have also been linked to prenatal sex steroids. For exam-
ple, prenatal levels of testosterone measured during 
amniocentesis are negatively correlated with the fre-
quency of eye-contact at 12 months [34] and, vocabulary 
size at 18 and 24  months [35], and are positively corre-
lated with restricted interests, attention to detail [29] and 
with autistic traits at 18 and 48 months [5, 6].
Epidemiological studies have revealed that maternal 
polycystic ovary syndrome (PCOS) increases the likeli-
hood of autism in their children [16, 17, 30]. This effect 
is not primarily driven by shared genetics and is further 
modulated by the sex of the offspring [15].
PCOS is a complex syndrome affecting between 4 and 
20% of women of reproductive age (depending on the 
diagnostic criteria), impacting their fertility, metabo-
lism and endocrine regulation [44]. It is particularly 
associated with higher baseline levels of androgens, as 
well as with a wider endocrine dysregulation during 
pregnancy (e.g. on placental function) [37]. Steroid-
related conditions such as PCOS and placental com-
plications are also more common in autistic people 
[17, 36, 40], and autistic adults demonstrate signs of 
steroid imbalance in various tissues [18, 28, 42]. Fur-
ther research is needed to understand the nature and 
timing of this endocrine imbalance in autism, as well 
as to study whether it extends to the wider spectrum of 
autistic traits in the general population.
The prenatal environment shows baseline sex differ-
ences in steroid production via the placenta [21], as well 
as in markers of placental formation and function, such 
as human choriogonadotropin (hCG) [1, 20, 38]. Atypical 
levels in both have been found in maternal serum of preg-
nancies that resulted in an autistic child, with both higher 
(for estradiol) and lower levels (for estriol) reported com-
pared to controls [13, 53]. However, these prenatal fac-
tors have not been studied together with fetal sex and in 
relation to both maternal and infant autistic traits.
To evaluate all these prenatal factors, we assessed both 
the mothers and their infants for autistic traits [via the 
Autism Spectrum Quotient (AQ) and Q-CHAT, respec-
tively] in a longitudinal cohort. We then tested whether 
steroid hormone levels (estradiol, testosterone, DHEAS, 
progesterone) and placental markers (e.g. hCG) in mater-
nal serum collected during the mother’s first ultrasound 
appointment predicted the autistic traits measured in 




Mothers were recruited during their pregnancy, during 
or immediately before their routine 20-week ultrasound 
scan [mean gestational age of 20.3 (SD = 0.4) weeks], 
between 2016 and 2018 at the Rosie Hospital, Cam-
bridge University Hospitals NHS Foundation Trust [7]. 
This study had been approved by the East of England 
Cambridge Central Research Ethics Committee (REC 
Ref 16/EE/0004) and the Research and Development 
Department of Cambridge University Hospitals. Eligibil-
ity inclusion criteria for the study were as follows: (1) lit-
tle/no consumption of alcohol during pregnancy, (2) no 
smoking or recreational drug use during pregnancy, and 
(3) a singleton pregnancy of a fetus (4) whose measure-
ments indicated their size to be appropriate for gesta-
tional age [no intrauterine growth restriction (IUGR) or 
large-for-gestational age (LGA)]. For the postnatal part 
of the study, the parents of all live singleton births were 
asked to take part in a series of developmental follow-ups 
during the first 2 years of life of their infant. Participat-
ing mothers also gave informed consent for access to 
all their pregnancy-related clinical records, test results, 
and the biological samples that were obtained during 
their routine clinical care of their pregnancy (both those 
acquired before as well as after the point of recruitment).
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Clinical data collection
Serum samples had been collected at the end of the first 
trimester [mean gestational age of 12.7 (SD = 0.7) weeks 
since conception] by a specialist phlebotomist at the 
Rosie Hospital, Cambridge. These were initially assayed 
for the levels of human choriogonadotropin (hCG) and 
pregnancy-associated peptide alpha (PAPP-A) as part of a 
national screening programme for biomarkers of Down’s 
Syndrome and other conditions, and any remaining 
serum was stored at – 80 °C. These samples were retro-
spectively linked to the participating mothers, following 
their recruitment at approximately 20-weeks gestation. 
A total of n = 122 of these samples were subsequently 
thawed and transferred to separate vials (1  ml aliquots 
per sample), which were further anonymised and sent for 
additional analysis at the Core Biochemical Assays Labo-
ratory (CBAL) at Addenbrookes Hospital, Cambridge. 
These corresponded to a subset of the study cohort 
(n = 219) (Fig.  1), since, in many instances, serum had 
been depleted or discarded after routine prenatal testing 
prior to recruitment.
In addition, mothers were asked to fill in a Pregnancy 
History Questionnaire (PHQ) at the point of recruit-
ment [mean gestational age of 20.3 (SD = 0.4) weeks]. 
The PHQ is a self-report inventory designed to collect 
information on metabolic, reproductive and clinically 
Fig. 1 Flow chart of the study, showing different cohort sizes for each comparison of autistic traits (AQ or Q‑CHAT) to prenatal measurements 
(steroid hormones or placental markers)
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diagnosed conditions of the mothers pertaining to their 
current  pregnancy, as well as those  previous. Maternal 
hirsutism was ascertained by the question ‘During your 
adult years, have you found coarse, dark hair, growing in 
any of the following areas?’, followed by drawings of mul-
tiple body areas that are prone to secondary hair growth 
(e.g. chest, lower face, upper or lower limbs), as described 
in previous studies [12].
Following labour, birth records containing information 
on neonate weight and gestational age at birth were also 
collected.
Additional assays
The following steroids and peptides were assessed in 
terms of concentration: Testosterone (T), Estradiol 
(E2), Dehydroepiandrosterone sulphate (DHEAS), Pro-
gesterone (P), sex hormone-binding globulin (SHBG). 
Samples were analysed on a DiaSorin Liaison® XL auto-
mated immunoassay analyser using a one-step competi-
tive chemiluminescence immunoassay for each hormone 
and two monoclonal antibodies for each peptide. All rea-
gents, standards and consumables are those supplied by 
DiaSorin [DiaSorin S.p.A, 13040 Saluggia (VC), Italy]. 
Batch quality precision data and concentration thresh-
olds of detection for each assay are reported in the Addi-
tional file 1 (Additional file 1: Table S1).
Autistic traits
Mothers were asked to complete the Autism Spectrum 
Quotient (AQ)—Adult version [11] during or immedi-
ately after their 20-week routine ultrasound scan at the 
Rosie Hospital [mean gestational age of 20.3 (SD = 0.4) 
weeks]. In addition, parents were invited via email to 
complete an online version of the Quantitative Check-
list for Autism in Toddlers (Q-CHAT) [3] after their 
infant reached 18  months of age (mean = 570.6  days, 
SD = 21.8 days).
All study data were collected and managed using RED-
Cap electronic data capture tools hosted at the University 
of Cambridge [24, 25].
Statistical analysis
Autistic trait distributions (maternal AQ and infant 
Q-CHAT) were assessed for extreme outliers, as defined 
by an interval of three times the interquartile range. If 
present, these were reduced to the highest possible value 
within the interval to facilitate statistical testing.
All steroid hormone concentration values exhib-
ited varying degrees of positive skew and were log-
transformed to reduce this and facilitate subsequent 
statistical testing via linear regression. Following this, 
outliers were preserved in the analysis to retain clini-
cal heterogeneity. Human choriogonadotropin (hCG) 
and pregnancy-associated peptide alpha (PAPP-A) val-
ues were retrieved from participants’ clinical records. 
These had been standardised according to multiple of the 
median (MoM) by the Prenatal Screening Department of 
the Trust according to maternal age, gestational age, and 
the national means [46, 54].
Multivariate analysis was conducted by calculating 
composite scores for the free fractions of estradiol  (E2) 
and testosterone  (T), and by estimating overall steroi-
dogenesis. The free testosterone index (FTI) and free 
estradiol index (FEI) were calculated via the following 
formulas (all concentrations in nmol/L) and then log-
transformed for further statistical analysis, as previously 
suggested [45]:
Latent factor analysis (‘nFactors’ package) was used to 
identify the optimal number of common steroidogenic 
factors based on their correlation matrix. Values for the 
predicted steroidogenic factor were calculated for each 
individual via the “Bartlett” method, based on the pre-
dicted loadings.
A series of clinical characteristics and group covari-
ates were assessed for pairwise association with autistic 
traits. In cases of binary traits, differences were tested 
via Student’s t-tests. These included comorbidity with 
PCOS or family history of autism, the latter being defined 
as present if the participating mothers reported having a 
first-degree relative (including previous child) that had 
been diagnosed with autism. A score of clinical severity 
of maternal hirsutism was devised based on responses 
in the Pregnancy History Questionnaire (PHQ), which 
the participating mothers completed following labour. 
A score of 1 denoted selection of one area of excess hair 
growth and 2 denoted more than one area. These were 
further treated as group variables (i.e. “no hirsutism”, 
“one area”, “more than one area”) and were used in cohort 
comparisons in terms of hormone levels and autistic 
traits.
Circulating hormones were log-transformed and 
assessed for association with autistic traits. For AQ, pair-
wise Pearson’s correlations were first used and then fol-
lowed-up with a linear regression model with AQ as the 
outcome variable and the following predictor variables: 
hormonal concentration, maternal age, comorbidity with 
PCOS. To account for potential underlying associations 
between infant sex and Q-CHAT scores, only multiple 
regression models were used in which an interaction 
term between infant sex and hormonal concentration 
was added (for each hormone separately), with Q-CHAT 
scores as the outcome, and addition of the following 
covariates: maternal age, maternal PCOS, maternal AQ 
FEI : (100 ∗ [E2])/([SHBG])
FTI : (100 ∗ [T ])/([SHBG])
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scores, and  infant age at assessment adjusted for ges-
tational age at birth. Family history of autism was not 
included as a covariate in these models, given the very 
small number of mothers with a diagnosed first-degree 
relative who also had available serum for hormone assays 
(n = 1 overlap).
The same approach and models were used when exam-
ining the hormone composite measures, namely FEI, FTI 
and the factors defined by unsupervised factor analysis of 
the steroid hormones.
To ensure their validity, multiple regression models 
with significant findings for AQ or Q-CHAT were fur-
ther tested for heteroscedasticity via the studentized 
Breusch–Pagan test and for the non-normality of their 
residuals via the Shapiro–Wilk test (Additional file  1: 
Table S8).
Results
Cohort characteristics and autistic traits
Of the n = 219 pregnant women who consented to take 
part in the study, n = 17 had a first-degree relative with 
autism, n = 26 had been diagnosed with PCOS, and 
n = 89 responded positively to having excess body hair 
growth in the past. Overall mean age of the mothers was 
32.4 years (SD = 4.54). Of this cohort, n = 189 completed 
the Autism Spectrum Quotient (AQ), with scores ranging 
from 1 to 47 (mean = 14.63, SD = 8.11) (Fig. 1).
Women with a family history of autism had a signifi-
cantly higher AQ score [n = 13, mean = 28 (SD = 14.36)] 
compared to women without any first-degree relatives 
with autism [n = 176, mean = 13.64 (SD = 6.51)] (Cohen’s 
D = 1.98, p = 0.004) (Table 1). Of the women who replied 
to both questionnaires, those who reported excess body 
hair in more than one area of their body (n = 51) also had 
significantly higher AQ scores [mean = 16.8 (SD = 6.7)], 
than those without any sign of excess body hair growth 
[n = 109, mean = 13.8 (SD = 8.9)] (Cohen’s D = 0.36, 
p = 0.021) (Fig.  2A). This effect persisted after control-
ling for family history of autism, maternal age and a diag-
nosis of PCOS via a linear regression model [Beta = 1.9 
(SE = 0.67), semipartial r = 0.18, p = 0.005] (Additional 
file 1: Table S2).
Of these pregnancies, n = 178 of the infants were 
followed-up with the Q-CHAT when they were older 
than 18 months of age (range 541–671 days after birth), 
with most being assessed between 18 and 20  months 
(mean = 570  days, SD = 21.3  days) (Fig.  1). Prior to sta-
tistical analysis, infant age was adjusted according to the 
gestational age at birth for each infant (mean = 39.56, 
SD = 1.5 weeks post-conception).
Regarding Q-CHAT scores, one extreme outlier was 
noted in the distribution (Q-CHAT = 71), which was 
reduced to the highest value within an interval of three 
times the interquartile range (Q-CHAT = 53), in order to 
reduce skewness and facilitate statistical comparisons.
There was no significant difference between Q-CHAT 
scores of male [mean = 30.35 (SD = 8.13)] and female 
[mean = 29.63 (SD = 7.58)] infants at this time-point of 
assessment (Cohen’s D = 0.09, p = 0.54).
Q-CHAT scores were significantly correlated with 
maternal AQ scores (Pearson’s r = 0.21, p = 0.008) (Addi-
tional file 1: Fig. S1).
Hormone covariates and factor analysis
Hormone concentrations were only available in sub-
sets of the cohort of women that consented to the study. 
This differed slightly for placental markers that were part 
of routine prenatal screening (hCG and PAPP-A) and 
steroid level measurements, which were analysed for 
research purposes on the remaining serum sample for 
each participant (Fig. 1).
The analysed maternal serum samples corresponded 
to a narrow period of gestation between the late 
first and early second trimester (mean = 12.7  weeks, 
SD = 0.8  weeks). Circulating hormones showed varying 
degrees of correlation with each other (Fig.  3) and with 
other demographic and clinical variables. Testosterone, 
DHEAS and progesterone were all positively correlated 
with maternal age (Additional file  1: Table  S3). Unsu-
pervised factor analysis showed that a common latent 
factor could be derived from estradiol, testosterone and 
DHEAS, which account for 32% of the total variance in 
hormone levels. The values for this ‘steroidogenic factor’ 
were estimated  for each participant based on the factor 
loadings and steroid  concentrations (Additional file  1: 
Figure S2).
Women with PCOS also had significantly higher levels 
of estradiol and progesterone, but lower levels of SHBG, 
compared to women without the condition (Additional 
file 1: Table S4). Maternal age correlated positively with 
progesterone, but negatively with testosterone, FTI and 
DHEAS (Additional file 1: Table S4). Women with a his-
tory of hirsutism in more than one area of their body 
also had significantly higher levels of estradiol (Cohen’s 
D = 0.47, p = 0.034) and FEI (Cohen’s D = 0.51, p = 0.025), 
as well as higher  predicted  values for  the latent steroid 
factor (D = 0.50, p = 0.028) (Fig. 2B).
Associations between hormones and maternal AQ score
The association between hormones in maternal serum 
and maternal autistic traits was investigated via univari-
ate Pearson’s correlation coefficient and with multiple 
regression (MR) controlled for maternal age and a diag-
nosis of PCOS (Table 2). FEI was significantly correlated 
with maternal AQ score using both methods (MR: semi-
partial r = 0.19, p = 0.048) (Fig. 4A). Estradiol levels were 
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Fig. 2 Violin‑boxplots showing the distribution of A maternal autistic traits (AQ) and B free estradiol levels (FEI), according to clinical history of 
hirsutism. Women that reported two or more body areas affected had significantly higher levels of both AQ (p = 0.021) and FEI (p = 0.025)
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associated with AQ in Pearson’s correlation (r = 0.20, 
p = 0.036), but this was not statistically significant in 
the multiple regression model that controlled for other 
covariates (MR: semipartial r = 0.11, p = 0.25).
Associations between hormones and infant Q-CHAT scores
Log-transformed concentrations of hormone levels 
were studied in relation to infant Q-CHAT with mul-
tiple linear regression models that controlled for birth 
weight, maternal PCOS, maternal AQ and infant age 
at the time of Q-CHAT, adjusted for gestational age at 
birth. The interaction between hormone concentration 
and infant sex was also used as a variable in the same 
model (Table  3). Infant sex moderated the association 
between maternal estradiol levels and Q-CHAT scores, 
with a positive association for Q-CHAT in males but not 
females (hormone-by-sex: semipartial r = 0.23, p = 0.036) 
(Table 3; Fig. 4B).
Standardised hCG MoM values were significantly 
associated with Q-CHAT scores, with a significant mod-
erating effect for infant sex (hormone-by-sex: semi-
partial r = −0.26, p = 0.005). This effect followed the 
opposite pattern to estradiol, with a positive relationship 
in females but not males (Table 3).
All multiple regression models that yielded significant 
results (for both AQ and Q-CHAT) passed tests on the 
assumptions of homoscedasticity and normality of resid-
uals (full model results: Additional file 1: Tables S6–S8).
Discussion
This is the first clinical longitudinal study to report on 
the endocrine profile of pregnant women and how this 
relates to their own autistic traits and to the autistic traits 
of their infants. First, we found that the fraction of free 
circulating estradiol (FEI) during pregnancy correlated 
positively with the autistic traits of pregnant neurotypi-
cal women. Second, we found that maternal estradiol was 
associated with infant autistic traits (as measured by the 
Q-CHAT) in a sex-dependent way, with a positive cor-
relation in males but not females. Third, we found that 
the opposite was true for standardised hCG MoM val-
ues, where a negative correlation with Q-CHAT scores in 
males was noted. These associations with early neurode-
velopment were independent of the mother’s AQ score or 
PCOS status, as well as other infant characteristics such 
as birth weight or age at the time of assessment. Finally, 
this is the first longitudinal study to show a significant 
positive correlation between maternal and infant autistic 
traits, as measured by the AQ and Q-CHAT, respectively.
Fig. 3 Heatmap and dendrogram of the pairwise correlations of the log‑transformed hormone concentrations. Values indicate the Pearson’s 
correlation coefficients
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The association between free circulating estradiol 
and maternal AQ was independent of maternal age or a 
diagnosis of PCOS. In addition, women with clinical his-
tory of excess body hair growth in more than one area 
of their body also had significantly higher autistic traits 
scores, as well as higher levels of circulating estradiol and 
FEI (Fig. 2). This is consistent with previous studies that 
reported higher rates of steroid-exposure related symp-
toms, such as hirsutism in autistic women [40]. The cor-
relation between FEI and AQ was independent of PCOS 
diagnostic status, and women diagnosed with PCOS did 
not have higher AQ scores (Table  1). This may be due 
to reduced statistical power (n = 13 with PCOS diagno-
sis) or the fact that all the women in this cohort had no 
autism diagnosis themselves and were without significant 
challenges in fertility, contrary to previous studies that 
found a link between PCOS and autism [17].
There was no association between testosterone levels 
or the FTI and maternal autistic traits in this study. Tes-
tosterone correlated positively with estradiol (Additional 
file 1: Table S3) but did not differ between women with 
and without PCOS, or correlate with a clinical history of 
hirsutism. Previous studies have also shown that circulat-
ing testosterone levels measured at a single time-point do 
not always correlate closely with their associated clinical 
parameters, such as hair growth [39]. Particularly during 
pregnancy, estradiol levels may be more clinically inform-
ative, as testosterone is rapidly aromatised into estradiol 
by the placenta. Estradiol could then be interpreted as 
the end-product of wider steroidogenesis and may be a 
better biomarker of the ‘steroidopathy’ previously indi-
cated by epidemiological studies of autistic women [40].
This is also the first study to investigate circulating 
hormones in maternal serum in relation to autistic traits 
in their infants measured between 18 and 20 months of 
age via the Q-CHAT. This questionnaire was developed 
to enable parents to quantify autistic traits, moving away 
from a restrictive binary format of items toward a Likert 
format. To date, the Q-CHAT has been validated in sev-
eral studies. Interestingly, the Q-CHAT also shows sex 
differences in early autistic traits, with males scoring sig-
nificantly higher than females in larger cohorts [2, 3, 41, 
43].
The current study found significant moderation effects 
of infant sex on the associations between hormones 
and neurodevelopment. Specifically, increased mater-
nal estradiol was more predictive of Q-CHAT scores of 
males than females (Fig. 4; Table 3). This was independ-
ent of potential confounding variables, such as mater-
nal age, diagnosis of PCOS and maternal autistic traits. 
Contrary to the results with the AQ, free estradiol levels 
(FEI), as estimated via serum SHBG, were not predic-
tive of Q-CHAT scores. SHBG is a peptide, and it does 
not cross the placenta as easily as steroids, as shown in 
rare cases of partial deficiency in mothers but not their 
fetus [26]. Maternal SHBG may therefore not accurately 
capture the bioavailability of steroids in the fetal circu-
lation nor  accurately predict potential effects on infant 
neurodevelopment.
Table 2 Pearson’s correlation (hormone and AQ) and multiple 
regression models (MR) for predicting AQ scores, controlled for 
maternal age and a diagnosis of PCOS
 *: p < 0.05, **: p < 0.01, ***: p < 0.001




Pearson’s r = 0.20 0.09 p = 0.036*
MR: intercept Beta = 4.52 12.29 p = 0.714
 Predictor Beta = 1.43 1.23 r = 0.11 p = 0.250
Testosterone
Pearson’s r = 0.09 0.10 p = 0.377
MR: intercept Beta = 17.34 4.50 p < 0.001***
 Predictor Beta = 0.34 1.12 r = 0.03 p = 0.761
DHEAS
Pearson’s r = 0.09 0.10 p = 0.379
MR: intercept Beta = 15.29 6.47 p = 0.020*
 Predictor Beta = 0.44 0.86 r = 0.05 p = 0.600
Progesterone
Pearson’s r = − 0.09 0.09 p = 0.365
MRa: intercept Beta = 23.23 6.94 p = 0.001**
 Predictor Beta = −2.16 2.22 r = −0.09 p = 0.334
hCG MoM
Pearson’s r = −0.03 0.08 p = 0.665
MR: intercept Beta = 13.92 0.97 p < 0.001***
 Predictor Beta = −0.27 0.58 r = −0.04 p = 0.650
PAPP-A MoM
Pearson’s r = −0.04 0.08 p = 0.589
MR : intercept Beta = 14.18 1.16 p < 0.001***




 Pearson’s r = 0.22 0.09 p = 0.019*
 MR: intercept Beta = 13.76 4.61 p = 0.004**
  Predictor Beta = 2.76 1.4 r = 0.19 p = 0.048*
Free Testosterone 
Index
 Pearson’s r = 0.11 0.10 p = 0.258
 MR: intercept Beta = 17.48 4.21 p < 0.001
  Predictor Beta = 0.69 4.21 r = 0.07 p = 0.484
Steroid factor
 Pearson’s r = 0.18 0.10 p = 0.061
 MR: intercept Beta = 16.75 0.09 p < 0.001***
  Predictor Beta = 0.77 0.55 r = 0.17 p = 0.085
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Further research is needed to understand the inter-
action between maternal estradiol levels and fetal sex 
in predicting Q-CHAT scores. As with the observed 
male bias in autism diagnoses, the lack of an association 
Fig. 4 Scatterplots with linear fit‑models for A the association between maternal free estradiol (FEI) and AQ score, and B the association between 
maternal estradiol and Q‑CHAT; separate linear models are presented for each sex and show significant interactions with infant sex in the case of 
infant Q‑CHAT
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between hormone levels in females may reflect behav-
ioural differences that are not adequately captured by 
this particular instrument [32]. Alternatively, this inter-
action may represent evidence of differential liability to 
prenatal hormone exposure, whereby males are affected 
more than females by the same maternal endocrine fac-
tors. Since males are undergoing an additional increase 
in steroid levels during mid-pregnancy, due to the acti-
vation of the testes, this interaction could also be attrib-
uted to the added effect of elevated steroids in the fetal 
circulation of males [51]. While fetal steroids were not 
measured directly in this study, previous comparisons in 
humans showed that estradiol levels correlated between 
maternal serum and amniotic fluid, in both the second 
and third trimesters [50]. The same was found for hCG 
levels in the second trimester [47]. In contrast, increases 
in androgen levels of male pregnancies were not detect-
able in maternal serum [50]. Therefore, the interaction of 
sex with estradiol levels in predicting Q-CHAT scores, 
in this study, could potentially be attributed to the addi-
tive effect of elevated androgens in the fetal circulation 
of males, which may not have been captured by assaying 
maternal serum, rather than amniotic fluid [5].
The findings with hCG mirror those for estradiol, 
showing a negative association with Q-CHAT scores in 
females but not males. hCG is produced by the develop-
ing trophoblast cells in the placenta and regulates early 
implantation as well as steroid production [14]. hCG lev-
els also show baseline sex differences in typical cohorts 
as early as the first half of pregnancy [1]. In the current 
cohort, hCG was measured late in the first trimester, 
during the first ultrasound visit, as part of the screen-
ing programme for Down’s syndrome. This is part of 
routine prenatal screening in the UK to test for placen-
tal dysfunction that can often be indicative of genomic 
instability due to aneuploidies [54]. In cases of clinically 
diagnosed autism, both very low and very high levels of 
hCG have been found in maternal serum, leading to a 
“U-shaped” association when studying both males and 
females [53]. Furthermore, autistic traits in the chil-
dren have been associated with the severity of nausea 
and ‘morning sickness’ during pregnancy, symptoms 
that have also been linked to high hCG levels [22, 52]. 
Further studies into placental functionality could offer 
insight into these observations, the role of sex, and more 
specifically, whether the observed interaction effect for 
Q-CHAT score is part of an adaptive response that is 
more pronounced in females than males.
Table 3 Multiple regression models for predicting Q‑CHAT 
scores and accounting for a hormone‑by‑sex interaction, further 
controlled for maternal AQ, a diagnosis of PCOS, maternal age, 
birth weight and infant age at Q‑CHAT assessment‑adjusted for 
gestational age at birth









MR: intercept Beta = 114.20 35.21 p = 0.002**
 Hormone Beta = −4.00 2.311 − 0.19 p = 0.087
 Hormone‑by‑sex Beta = 8.27 4.08 0.23 p = 0.036*
Testosterone
MR: intercept Beta = 80.01 29.07 p = 0.007**
 Hormone Beta = −1.95 2.12 − 0.10 p = 0.362
 Hormone‑by‑sex Beta = 0.99 3.28 0.03 p = 0.765
DHEAS
MR: intercept Beta = 90.03 29.68 p = 0.003**
 Hormone Beta = −2.33 1.58 − 0.16 p = 0.144
 Hormone‑by‑sex Beta = 1.36 3.22 0.04 p = 0.674
Progesterone
MR : intercept Beta = 84.06 32.16 p = 0.011*
 Hormone Beta = −3.70 4.65 − 0.08 p = 0.429
 Hormone‑by‑sex Beta = 11.64 6.86 0.18 p = 0.095
hCG MoM
MR: intercept Beta = 34.2 20.61 p = 0.100
 Hormone Beta = 2.95 1.07 0.24 p= 0.007**
 Hormone‑by‑sex Beta = −4.34 1.53 − 0.25 p = 0.005**
PAPP-A MoM
MR: intercept Beta = 46.04 21.13 p = 0.031*
 Hormone Beta = 1.69 1.45 0.11 p = 0.245




 MR: intercept Beta = 82.42 29.02 p = 0.006**
  Hormone Beta = −0.969 1.37 − 0.07 p = 0.481
  Hormone‑by‑sex Beta = 1.989 1.68 0.13 p = 0.240
Free Testosterone 
Index
 MR: intercept Beta = 77.86 29.16 p = 0.009**
  Hormone Beta = 2.50 8.78 r = 0.03 p = 0.777
  Hormone‑by‑sex Beta = −9.53 11.69 r = −0.09 p = 0.417
Steroid factor
 MR: intercept Beta = 85.95 29.01 p = 0.004**
  Hormone Beta = −1.95 1.20 r = −0.17 p = 0.108
  Hormone‑by‑sex Beta = 2.80 1.81 r = 0.16 p = 0.126
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Limitations
Limitations of the current study include the relatively 
small sample size, as well as potential ascertainment bias 
given the voluntary process of recruitment. In addition, 
AQ and Q-CHAT scores were both rated by the mother 
herself. This was addressed by controlling for maternal AQ 
when studying associations between hormones and infant 
Q-CHAT scores. The items of the AQ-Adult and Q-CHAT 
are also substantially different, with the latter dealing with 
behavioural and developmental milestones that are spe-
cific to infants rather than to interests and personality 
traits that are more evident in adulthood. Furthermore, 
the findings of the current study may have been inflated by 
Type I errors, as p value thresholds were not corrected for 
multiple testing. However, the findings on estradiol were 
consistent for both maternal and infant outcomes (Fig. 4), 
were reflected in clinical hirsutism differences (Fig. 2), and 
are in accordance with those observed in other studies 
of clinical autism [10, 13]. The high degree of correlation 
between many of the assessed hormones (Fig. 3) also indi-
cates a common functional and regulatory framework. The 
association tests for individual hormones may therefore 
not be entirely independent, but instead affected by a com-
mon steroidogenic factor as previously reported [9]. Rep-
lication of these findings in a larger, independent cohort is 
warranted to confirm their validity.
Conclusions
This is the first longitudinal study to report associations 
between maternal steroidogenic factors and the autistic 
traits of both the mother and her infant, with signifi-
cant moderating effects of sex being noted for the latter. 
Additional research is needed to replicate these findings, 
to establish how maternal steroidogenesis may affect 
fetal neurodevelopment, and to determine how these 
processes interact with genetics to disproportionately 
increase the liability for autism in males.
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